{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T02:21:45Z","timestamp":1706840505866},"reference-count":27,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,8,19]],"date-time":"2013-08-19T00:00:00Z","timestamp":1376870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Anaesthesiol Scand"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Sevoflurane is a known triggering agent of malignant hyperthermia (<jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>). The present study analyzed different effects of sevoflurane on skeletal muscle of MH susceptible and nonsusceptible individuals in vitro and compared the results to the standardized test protocol with halothane and caffeine. A potential influence of a present ryanodine receptor type 1 (<jats:styled-content style=\"fixed-case\">RyR1<\/jats:styled-content>) mutation was investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Muscle bundles of 24 <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\u2010susceptible patients with or without an <jats:styled-content style=\"fixed-case\">RyR1<\/jats:styled-content> mutation, 35 <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\u2010nonsusceptible and 10 <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\u2010equivocal patients were exposed either to sevoflurane 8 vol% bolus or increasing doses of 2, 4, 6, and 8 vol%. In <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\u2010positive patients, a screening for mutations in the <jats:styled-content style=\"fixed-case\">RyR1<\/jats:styled-content> gene was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The in vitro parameters initial length, weight, predrug resting tension, and predrug twitch height did not differ between the groups. Sevoflurane caused significant contractures in <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\u2010susceptible but not in <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\u2010nonsusceptible muscle after increasing doses [1.4 (0.3\u20136.0) vs. 0 (0\u20100) mN] and after bolus application [6.9 (2.4\u201321.4) vs. 0 (0\u20100) mN]. However, only 50% of the susceptible patients developed contractures \u2265\u20092\u2009mN after increasing concentrations while 83% did so after rapid bolus administration. Presence of an <jats:styled-content style=\"fixed-case\">RyR1<\/jats:styled-content> mutation was detected in 36% of the examined <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content>\u2010positive patients but had no influence on developing contractures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Sevoflurane\u2010induced contractures do not reliably detect <jats:styled-content style=\"fixed-case\">MH<\/jats:styled-content> susceptibility on an individual level. Therefore, sevoflurane is no suitable alternative for diagnostic use. Mutation\u2010specific effects regarding contracture sizes after incubation with sevoflurane, halothane, or caffeine were not found.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aas.12171","type":"journal-article","created":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T02:06:42Z","timestamp":1376964402000},"page":"1161-1166","source":"Crossref","is-referenced-by-count":4,"title":["Sevoflurane is less sensitive than halothane for in vitro detection of malignant hyperthermia susceptibility"],"prefix":"10.1111","volume":"57","author":[{"given":"S.","family":"JOHANNSEN","sequence":"first","affiliation":[{"name":"Department of Anaesthesia and Critical Care University of Wuerzburg  Wuerzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"KLINGLER","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia Ulm University  Ulm Germany"},{"name":"Division of Neurophysiology Ulm University  Ulm Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"SCHNEIDERBANGER","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia and Critical Care University of Wuerzburg  Wuerzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"HEIDERICH","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia Ulm University  Ulm Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"ROEWER","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia and Critical Care University of Wuerzburg  Wuerzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"SCHUSTER","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia and Critical Care University of Wuerzburg  Wuerzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-21"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1242125"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/56.11.1267"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-198910000-00015"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199211000-00054"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199503000-00031"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-995126"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0001-5172.2004.00451.x"},{"key":"e_1_2_7_10_1","first-page":"153","article-title":"[Delayed onset of malignant hyperthermia crisis during a living donor liver transplantation caused by sevoflurane]","volume":"39","author":"Gillmeister I","year":"2004","journal-title":"Anasthesiol Intensivmed Notfallmed Schmerzther"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annfar.2009.09.008"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198103000-00020"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.anes.0000281915.85577.1a"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-6576.2000.440320.x"},{"key":"e_1_2_7_15_1","first-page":"311P","article-title":"In vitro skeletal muscle contracture responses to sevoflurane \u2013 a potential diagnostic test for malignant hyperthermia susceptibility?","volume":"92","author":"Hopkins P","year":"2004","journal-title":"Br J Anaesth"},{"key":"e_1_2_7_16_1","first-page":"768","article-title":"Sevoflurane as a potential replacement for halothane in diagnostic testing for malignant hyperthermia susceptibility: results of a preliminary study","volume":"77","author":"Metterlein T","year":"2011","journal-title":"Minerva Anestesiol"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/EJA.0b013e32833ed06c","article-title":"In\u2010vitro contracture testing for susceptibility to malignant hyperthermia: can halothane be replaced?","volume":"28","author":"Metterlein T","year":"2010","journal-title":"Eur J Anaesthesiol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000160534.23519.1B"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1997.tb04820.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199803000-00006"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1726-4901(08)70050-9"},{"key":"e_1_2_7_22_1","first-page":"189","article-title":"Delayed onset of sevoflurane\u2010induced juvenile malignant hyperthermia after second exposure","volume":"45","author":"Chen PL","year":"2007","journal-title":"Acta Anaesthesiol Taiwan"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2009.03159.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199907000-00026"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/ael179"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/86.2.283"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0001-5172.2004.00461.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-6576.2002.460914.x"}],"container-title":["Acta Anaesthesiologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faas.12171","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aas.12171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T06:42:02Z","timestamp":1696488122000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aas.12171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,19]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/aas.12171"],"URL":"https:\/\/doi.org\/10.1111\/aas.12171","archive":["Portico"],"relation":{},"ISSN":["0001-5172","1399-6576"],"issn-type":[{"value":"0001-5172","type":"print"},{"value":"1399-6576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,19]]}}}